Page last updated at 08:01 GMT, Tuesday, 20 April 2010 09:01 UK

Novartis profits lifted by swine flu vaccine

Flu vaccination
Contracts for swine flu vaccines agreed in 2009 boosted Novartis's results

Profits at Swiss drugmaker Novartis have risen by almost a third, boosted by sales of its flu vaccine made during the swine flu pandemic.

The firm made a net profit of $2.95bn (£1.93bn) in the first quarter of 2010, compared with a $1.98bn profit for the same quarter a year earlier.

Sales rose 25% to $12bn. The news sent Novartis shares up 1.4% in Zurich.

The firm said it expected sales growth in the year ahead to be boosted by its pharmaceuticals division.

"The strong sales and profit contributions in the first quarter of 2010 from fulfilment of agreed-upon government supply contracts for A (H1N1) pandemic vaccines, with sales approximately $400m above the group's target at the beginning of the year, will further strengthen these prospects," Novartis said in a statement.

Novartis has agreed to buy a majority stake in eyecare company Alcon from Nestle and said the deal made it difficult to make profit forecasts.



Print Sponsor


SEE ALSO
UK swine flu vaccine 'approved'
25 Sep 09 |  Health
Novartis in $40bn Alcon takeover
04 Jan 10 |  Business

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites



FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC iD

Sign in

BBC navigation

Copyright © 2018 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific